EPC 002
Alternative Names: EPC-002Latest Information Update: 31 Jul 2025
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Glioblastoma
Most Recent Events
- 28 Jul 2025 Elpis Biopharmaceuticals collaborates with NCCS to accelerate development of bispecific armored CAR-T therapies for solid tumors in Singapore
- 28 Apr 2025 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2025
- 28 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumours released by Elpis Biopharmaceuticals